Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

STAT3 Inhibition as a Therapeutic Strategy for Chordoma.

Wang AC, Owen JH, Abuzeid WM, Hervey-Jumper SL, He X, Gurrea M, Lin M, Altshuler DB, Keep RF, Prince ME, Carey TE, Fan X, McKean EL, Sullivan SE.

J Neurol Surg B Skull Base. 2016 Dec;77(6):510-520. Epub 2016 May 31.

PMID:
27857879
2.

A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.

Zhao C, Wang W, Yu W, Jou D, Wang Y, Ma H, Xiao H, Qin H, Zhang C, Lü J, Li S, Li C, Lin J, Lin L.

Oncotarget. 2016 Mar 15;7(11):12917-26. doi: 10.18632/oncotarget.7338.

3.

Interferon-γ suppresses intestinal epithelial aquaporin-1 expression via Janus kinase and STAT3 activation.

Dicay MS, Hirota CL, Ronaghan NJ, Peplowski MA, Zaheer RS, Carati CA, MacNaughton WK.

PLoS One. 2015 Mar 20;10(3):e0118713. doi: 10.1371/journal.pone.0118713. eCollection 2015.

4.

Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.

Jiang X, Kanda T, Wu S, Nakamoto S, Saito K, Shirasawa H, Kiyohara T, Ishii K, Wakita T, Okamoto H, Yokosuka O.

PLoS One. 2014 Jul 7;9(7):e101993. doi: 10.1371/journal.pone.0101993. eCollection 2014.

5.

MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug.

Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, Hornicek FJ, Duan Z.

J Orthop Res. 2014 Aug;32(8):1075-82. doi: 10.1002/jor.22632. Epub 2014 Apr 24.

6.

Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets.

Walker SR, Frank DA.

JAKSTAT. 2012 Oct 1;1(4):292-9. doi: 10.4161/jkst.22662. Review.

7.

GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK.

Blood. 2013 Jun 20;121(25):5068-77. doi: 10.1182/blood-2012-10-460170. Epub 2013 Apr 30.

8.

The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms.

Lu Z, Bast RC Jr.

Cell Adh Migr. 2013 Mar-Apr;7(2):232-6. doi: 10.4161/cam.23648. Epub 2013 Jan 28.

9.

Identification of novel host-targeted compounds that protect from anthrax lethal toxin-induced cell death.

Slater LH, Hett EC, Mark K, Chumbler NM, Patel D, Lacy DB, Collier RJ, Hung DT.

ACS Chem Biol. 2013 Apr 19;8(4):812-22. doi: 10.1021/cb300555n. Epub 2013 Feb 4.

10.

Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells.

Kim SY, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT, Lee YJ.

Cell Signal. 2013 Apr;25(4):961-9. doi: 10.1016/j.cellsig.2013.01.007. Epub 2013 Jan 16.

11.
12.

MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration.

Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H, Hornicek F.

Mol Cancer Ther. 2011 Aug;10(8):1337-45. doi: 10.1158/1535-7163.MCT-11-0096. Epub 2011 Jun 10.

13.

The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.

Ball S, Li C, Li PK, Lin J.

PLoS One. 2011 Apr 19;6(4):e18820. doi: 10.1371/journal.pone.0018820.

14.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA.

Blood. 2010 Oct 28;116(17):3268-77. doi: 10.1182/blood-2010-05-282780. Epub 2010 Jul 13.

15.

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.

Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z.

BMC Cancer. 2010 May 10;10:187. doi: 10.1186/1471-2407-10-187.

16.

Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.

Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li PK, Li C, Fuchs J, Lin J.

Cancer Res. 2010 Mar 15;70(6):2445-54. doi: 10.1158/0008-5472.CAN-09-2468. Epub 2010 Mar 9.

17.

A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.

Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J.

Neoplasia. 2010 Jan;12(1):39-50.

18.

Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.

Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B.

Ann N Y Acad Sci. 2009 Aug;1171:59-76. doi: 10.1111/j.1749-6632.2009.04911.x. Review.

19.

A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical libraries.

Johnson RL, Huang R, Jadhav A, Southall N, Wichterman J, MacArthur R, Xia M, Bi K, Printen J, Austin CP, Inglese J.

Mol Biosyst. 2009 Sep;5(9):1039-50. doi: 10.1039/b902021g. Epub 2009 Jun 19.

20.

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.

Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T, Kage M, Hori D, Kamura T.

Br J Cancer. 2009 Sep 15;101(6):967-72. doi: 10.1038/sj.bjc.6605212. Epub 2009 Jul 28.

Supplemental Content

Support Center